XTL-6865 Uses, Dosage, Side Effects and more
XTL-6865 is a combination of two fully human monoclonal antibodies (Ab68 and Ab65) against the hepatitis C virus E2 envelope protein. It is being developed to prevent HCV re-infection following a liver transplant and for the treatment of chronic HCV disease.
| Trade Name | XTL-6865 |
| Generic | XTL-6865 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in hepatitis (viral, C).
How XTL-6865 works
XTL-6865 is a dual-antibody (Ab68 and Ab65) therapy directed against the highly mutagenic hepatitis C E2 envelope protein and intended therefore to inhibit viral entry into host cells.
